The Pharmaceutical Industry and ICH Q9

Slides:



Advertisements
Similar presentations
Risk Analysis Fundamentals and Application Robert L. Griffin International Plant Protection Convention Food and Agriculture Organization of the UN.
Advertisements

Options appraisal, the business case & procurement
Page 1 Capability Business Benefit Business Risk KEYBA Capabilities: Benefits V Risks Facilitation of Decision making Getting the right people together.
Better risk management in support of regulatory quality Incorporating risk assessment tools in RIA to prepare better rules Charles-Henri Montin Senior.
Introduction to the Supply Chain Risk Management Guide RPSGB, London 23 rd February 2010 Jill Jenkins - Pharmaceutical Quality Group.
1 Supply Chain Risk Management Guide Toolbox & Examples RPSGB, London 23 rd February 2010 Justin Ahern - PQG.
What’s New in the FDA’s Pharmaceutical Inspectorate and Risk Based Systems Inspection Rick Perlman Chair Food, Drug, and Cosmetic Division ASQ.
2011 Governance, Risk, and Compliance Conference August 29 – 31, 2011 / Orlando, FL, USA The Top Four Essential Objectives to Auditing ERM Stephen E. McBride,
Define ● Deliver ● Sustain Sundar Chellamani Technical Director SysComm Project Management Ltd.
The Australian/New Zealand Standard on Risk Management
Title slide PIPELINE QRA SEMINAR. PIPELINE RISK ASSESSMENT INTRODUCTION TO GENERAL RISK MANAGEMENT 2.
PSCI PHARMACEUTICAL SUPPLY CHAIN INITIATIVE The Pharmaceutical Supply Chain Initiative – An Overview Presented by [Add name] [Add role title] [Add company.
Tony Gould Quality Risk Management. 2 | PQ Workshop, Abu Dhabi | October 2010 Introduction Risk management is not new – we do it informally all the time.
Annex I: Methods & Tools prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY.
Quality System Model ICH Q10
History and Background to the HACCP System
Systemise your compliance management Peter Scott Consulting
Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science July 20-21, 2004 Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.
Frequently Asked Questions (FAQ) prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9.
Quality Risk Management ICH Q9 Content
ICH Q9: Quality Risk Management
Quality Risk Management ICH Q9 Annex I: Methods & Tools
Pilot Risk-Ranking Model to Prioritize Manufacturing Sites for GMP Inspections Advisory Committee for Pharmaceutical Science Manufacturing Subcommittee.
Presentation on Integrating Management Systems
FAO/WHO CODEX TRAINING PACKAGE
FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.
Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.
Implementing QRM as a New Quality System
Ashland Specialty Ingredients IFAC’s cGMP Audit Guide How the Food Ingredient Industry has Responded to FSMA and Food Safety Audits Priscilla Zawislak.
Mike Murray Chair of EFPIA EH&S AHG MPA Conference Uppsala
Global Risk Management Solutions Risk Management and the Board of Director: Moving Beyond Concepts to Execution Anton VAN WYK Partner, Global Risk Management.
Risk Management Report to Audit Committee 26 September 2006 Lee Harris Assistant Chief Executive.
Tom Cecich, CSP, CIH NC Chapter ASSE March 12, 2015.
Annex II: Potential Applications prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9.
Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.
Quality Management.  Quality management is becoming increasingly important to the leadership and management of all organisations. I  t is necessary.
© 2011 Underwriters Laboratories Inc. All rights reserved. This document may not be reproduced or distributed without authorization. ASSET Safety Management.
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
CHALLENGING BOUNDARIES Rhodia way, The way we do business.
Management & Development of Complex Projects Course Code MS Project Management Perform Qualitative Risk Analysis Lecture # 25.
QUALITY RISK MANAGEMENT RASHID MAHMOOD MSc. Analytical Chemistry MS in Total Quality Management Senior Manager Quality Assurance Nabiqasim Group of Industries.
RISK MANAGEMENT The process of weighing policy alternatives in the light of the results of risk assessment and, if required, selecting and implementing.
SECTION IV: GENERAL DESCRIPTION OF STEPS TAKEN OR ENVISAGED BY NON-ANNEX I PARTY TO IMPLEMENT THE CONVENTION Workshop on the Use of the Guidelines for.
Annex I: Methods & Tools prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY.
Annex II: Potential Applications prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9.
PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.
Molecule-to-Market-Place Quality
Responsible Care® Health & Safety Task Force – 06 H&S.
Breakout D Quality Risk Management
Integral Health Solutions We make healthcare systems work in harmony.
Kathy Corbiere Service Delivery and Performance Commission
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Pharmaceutical Manufacturing Subcommittee of the ACPS Ajaz S. Hussain, Ph.D. ACPS Meeting October 22, 2002.
CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.
Risk Management and the Audit Plan abc CIPFA in the Midlands Audit Training Seminar Wednesday 24th November 2004 Tina Spiers.
Drug Quality Regulations for the 21 st Century PhRMA Perspective Manufacturing Subcommittee Meeting – May 21, 2003 Gerry Migliaccio Pfizer Inc.
PIC EU-28 Conference Paris, 26 – 27 November 2015 PIC An EU Approach Assurance Maps An Introductory workshop Nathan Paget United Kingdom.
“Total Quality Management and Quality Risk Management” By: Pratitha Naik Parsekar Quality Assurance VerGo Pharma Research laboratory Pvt Ltd. Date: 16-Mar-2016.
RISK MANAGEMENT FOR COMMUNITY EVENTS. Today’s Session Risk Management – why is it important? Risk Management and Risk Assessment concepts Steps in the.
November 6, 2013 Purchasing Controls & Supplier Quality Best Practices Beyond Compliance for the Medical Device Industry AdvaMed 2013 Bernie Liebler Technology.
An Overview on Risk Management
Quality Risk Management
Food Production Systems
Quality Risk Management
Quality System.
MOSH Leading Practices Adoption System
ICH Q9: Quality Risk Management
ICH Q9: Quality Risk Management
Quality Risk Management ICH Q9 Frequently Asked Questions (FAQ)
Pharmaceutical Quality Group David Abraham
Presentation transcript:

The Pharmaceutical Industry and ICH Q9 Peter H Gough Partner, David Begg Associates 1

21st Century GMP Initiative “Seeks to integrate quality systems and risk management approaches into the existing programmes and encourages adoption of modern and innovative manufacturing technology.” “Use existing and emerging science and analysis to ensure that limited resources are best targeted to address important quality issues, especially those associated with predictable or identifiable health risks.” Lester M. Crawford, FDA Deputy Commissioner, 21 August 2002 2

FDA’s “Desired State” Regulatory policies tailored to recognise the level of scientific knowledge supporting applications, process validation and process capability Risk-based scrutiny related to: Level of scientific understanding Capability of process control strategies to prevent or mitigate risk of producing a poor quality product 3

International Conference on Harmonisation (ICH) EU and Japan joined USA to define a new paradigm at an ICH GMP Workshop in Brussels, July 2003 4

ICH – Structure and Members Q uality S afety E fficacy M ultidisciplinary Expert Working Groups (EWGs) 5

ICH GMP Workshop ICH GMP Workshop in Brussels, July 2003 This Workshop agreed a 5 year Vision: Create a single, harmonised global quality standard and interpretation based on good science and risk management principles 6

Incremental Steps to Achieve the Vision The GMP Workshop agreed that the Vision would be achieved by ‘incremental steps’: Q8 EWG, on Pharmaceutical Development, established in September 2003 Q9 EWG, on Quality Risk Management, established in November 2003 Q10 EWG, on Pharmaceutical Quality System, established in November 2005 7

Achieve by Incremental Steps Pharmaceutical Development (Q8) Old: Data transfer / variable output New: Knowledge transfer / Consistent output Changed Paradigm Quality Risk Management (Q9) Old: Unstructured approach New: Opportunity to use a structured process Quality Systems (Q10) Old: Large variability on Q-systems New: Consistency on Q-systems Q8 Q10 Q9 8

Risk Management We all do risk management every day Driving to work Extreme sports Everything in life has some degree of risk Can NEVER have zero risk We all manage risk but we have different risk thresholds 9

10

11

12

If you do not manage risk; it will manage you. Risk and Management If you do not manage risk; it will manage you. 13

What is Risk Management? PROACTIVELY: Identifying risks (what can go wrong?) Analysing risks Evaluating risks Controlling and reducing these risks Accepting residual risk 14

Pharmaceutical Industry and Risk Management Pharmaceuticals have lagged behind related industries in adopting formal risk management, e.g. Medical devices, ISO 14971 Food, HACCP We are using risk management but historically Implementation was patchy It was often not fully integrated with rest of the Quality System Was performed retrospectively 15

Quality Risk Management Pharmaceutical Quality Risk Management is about: Knowing your processes (manufacturing and business) Identifying what’s truly important Focusing your money, time, energy and people on the things that are really important, i.e. things which have potential to impact patients 16

Advantages of Risk Management Systematic, scientific and data-driven process Reduces subjectivity Ranks risk - allows prioritisation Improves decision making Identifies what gives most benefit to the patient Documented - improves communication 17

Risk Management Must do risk management properly Poor risk management will not impress regulators They will think we do not know what’s really important If everything is critical, nothing is critical Ultimately, it is about credibility Have to begin with the question “What is the impact on the patient?” 18

Why Did We Need ICH Q9 ? Needed ICH Q9 to: Explain what quality risk management is and how it can be applied to pharmaceuticals Provide a common language and an agreed process for the pharmaceutical industry and regulators 19

Why Did We Need ICH Q9? To ensure both industry and regulators have common understanding of Quality Risk Management (QRM) To facilitate moving to the ‘Desired State’ To facilitate communication and transparency To move from ‘fire fighting’ to management of risk 20

ICH Q9 Definitions Harm = damage to health, including the damage that can occur from loss of product quality or availability Hazard = potential source of harm Risk = combination of probability of harm and severity of that harm These are the definitions used in the ICH Q9 Guideline on Quality Risk Management. 21

What Does ICH Q9 Deliver? ICH Q9 provides: The key principles of QRM A common language and process Potential methodologies for QRM Potential applications where QRM can add value 22

ICH Q9 – Principles of Quality Risk Management Two primary principles: 1. The evaluation of the quality risk should be based on scientific knowledge and ultimately link back to the protection of the patient 2. The level of effort, formality and documentation of the quality risk management process should be commensurate with the level of risk 23

ICH Q9 Quality Risk Management Process Initiate Quality Risk Management Process Risk Assessment Risk Communication Risk Identification Risk Analysis unacceptable Risk Management Tools Risk Evaluation Risk Control Risk Reduction Risk Acceptance Output / Results of the Risk Management Process Risk Review Review Events 24 24

ICH Q9 – Annex 2 Potential Applications for Quality Risk Management To provide a comprehensive evaluation of suppliers and contract manufacturers (e.g., auditing, supplier quality agreements) To provide information for ensuring the availability of pharmaceuticals (e.g., ranking risks to the supply chain) 25

Supply Chain Risks Recent events have exposed several areas of risk: Heparin contamination is USA and elsewhere Melamine contamination of milk in China Further cases of diethylene glycol contamination of glycerol Counterfeit products entering the legitimate supply chain in the EU 26

Supply Chain Risks These supply chain risks are real Probably rank amongst the highest hazards currently faced The must be managed proactively ICH Q9 and this PQG Guide provide an excellent approach 27

PQG Supply Chain Risk Management When we wrote Q9 we hoped it would encourage greater understanding of risk & risk management in the pharmaceutical industry This PQG Guide is exactly the type of detailed thinking that we hoped to see 28

Watch Out ! To add value QRM must be done properly You must have the right experts on your team You must consider all reasonable hazards You must use the right weightings for hazards Ultimately it must be about the patient 29

Watch Out ! FMEA Risk Priority Numbers The absolute number is unimportant RPN allows risks to be ranked Allows action to be prioritised Provides justifiable basis for decision making… including doing nothing! 30

Conclusion We are already doing Quality Risk Management Using a structured, systematic process adds value in many more complex situations Supply Chains are complex! The PQG Guide provides a good framework Use it pro-actively 31

Thank you DBA David Begg Associates www.DBA-global.com 32